Mortazavi 2011.

Methods	Study design: parallel RCT Study duration: December 2009 to March 2010 Duration of follow‐up:
Participants	Setting: multicentre (2) Country: Iran Participants > 18 years, being dialysed with central tunnelled catheter (only if placed in the internal jugular vein), with a maximum time of 1 month post catheterisation, dialysis 3 times a week and having accepted to participate Number (participants/catheters): treatment group (15/15); control group (15/15) Mean age ± SD (years): treatment group (52 ± 10.30); control group (56 ± 9.6) Sex (M/F): treatment group (7/8); control group (6/9) Exclusion criteria: allergy to cefotaxime; antibiotic treatment within 2 weeks prior to enrolment; participants requiring a surrogate decision maker; catheters with blood flow rates < 300 mL/min, or requiring frequent thrombolytic solution dwells in the catheter lumen because of malfunction
Interventions	Treatment group Cefotaxime: 10 mg/mL Heparin: 5000 UI/mL Control group Heparin: 5000 U/mL
Outcomes	CRI
Notes	Funding source: " No financial support received in support of the study:
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Used randomisation computerized block protocol
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double‐blind study, probably were blind
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient data reported
Selective reporting (reporting bias)	Low risk	Describes the outcome according to objective
Other bias	Unclear risk	Insufficient information to permit judgement